Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:ELVN NASDAQ:IMTX NASDAQ:PRAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.23-18.5%$1.17$0.86▼$3.78$272.91M0.433.35 million shs7.20 million shsELVNEnliven Therapeutics$20.82-2.2%$19.73$13.30▼$30.03$1.23B0.85578,428 shs546,587 shsIMTXImmatics$10.36-5.0%$6.73$3.30▼$10.95$1.26B1.221.09 million shs1.22 million shsPRAXPraxis Precision Medicines$53.26-2.7%$47.32$26.70▼$91.83$1.12B2.62427,775 shs243,344 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%-7.52%+5.13%-3.91%-53.41%ELVNEnliven Therapeutics0.00%+6.17%+4.52%-7.26%-26.20%IMTXImmatics0.00%+10.21%+75.00%+73.53%-6.41%PRAXPraxis Precision Medicines0.00%-2.06%+35.11%+5.38%-15.51%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.23-18.5%$1.17$0.86▼$3.78$272.91M0.433.35 million shs7.20 million shsELVNEnliven Therapeutics$20.82-2.2%$19.73$13.30▼$30.03$1.23B0.85578,428 shs546,587 shsIMTXImmatics$10.36-5.0%$6.73$3.30▼$10.95$1.26B1.221.09 million shs1.22 million shsPRAXPraxis Precision Medicines$53.26-2.7%$47.32$26.70▼$91.83$1.12B2.62427,775 shs243,344 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics0.00%-7.52%+5.13%-3.91%-53.41%ELVNEnliven Therapeutics0.00%+6.17%+4.52%-7.26%-26.20%IMTXImmatics0.00%+10.21%+75.00%+73.53%-6.41%PRAXPraxis Precision Medicines0.00%-2.06%+35.11%+5.38%-15.51%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.54Moderate Buy$8.44586.54% UpsideELVNEnliven Therapeutics 2.67Moderate Buy$41.2097.89% UpsideIMTXImmatics 2.57Moderate Buy$13.6731.92% UpsidePRAXPraxis Precision Medicines 2.75Moderate Buy$85.5660.64% UpsideCurrent Analyst Ratings BreakdownLatest ALLO, ELVN, PRAX, and IMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/10/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight10/8/2025ALLOAllogene TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025ELVNEnliven TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025IMTXImmaticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025PRAXPraxis Precision MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ALLOAllogene TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ELVNEnliven TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMTXImmaticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025PRAXPraxis Precision MedicinesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/18/2025IMTXImmaticsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.009/18/2025PRAXPraxis Precision MedicinesJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$83.00(Data available from 10/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K13,645.62N/AN/A$2.01 per share0.61ELVNEnliven TherapeuticsN/AN/AN/AN/A$6.34 per shareN/AIMTXImmatics$168.65M7.47$0.24 per share42.40$5.12 per share2.02PRAXPraxis Precision Medicines$8.55M131.13N/AN/A$23.90 per share2.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)ELVNEnliven Therapeutics-$89.02M-$2.00N/AN/AN/AN/A-29.15%-27.88%11/12/2025 (Estimated)IMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$12.29N/AN/AN/AN/A-60.07%-54.84%11/5/2025 (Estimated)Latest ALLO, ELVN, PRAX, and IMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025ALLOAllogene Therapeutics-$0.23N/AN/AN/AN/AN/A11/5/2025Q3 2025PRAXPraxis Precision Medicines-$3.45N/AN/AN/A$0.06 millionN/A8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/13/2025Q2 2025ELVNEnliven Therapeutics-$0.53-$0.49+$0.04-$0.49N/AN/A8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/4/2025Q2 2025 & Study ResultPRAXPraxis Precision Medicines-$3.40-$3.31+$0.09-$3.31$0.15 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A8.928.92ELVNEnliven TherapeuticsN/A32.5832.58IMTXImmaticsN/A8.808.80PRAXPraxis Precision MedicinesN/A6.316.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%ELVNEnliven Therapeutics95.08%IMTXImmatics64.41%PRAXPraxis Precision Medicines67.84%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%ELVNEnliven Therapeutics25.90%IMTXImmaticsN/APRAXPraxis Precision Medicines2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionableELVNEnliven Therapeutics5059.24 million43.89 millionOptionableIMTXImmatics260121.55 millionN/AOptionablePRAXPraxis Precision Medicines11021.05 million20.48 millionOptionableALLO, ELVN, PRAX, and IMTX HeadlinesRecent News About These CompaniesPraxis Precision Medicines (NASDAQ:PRAX) Receives Sell (D-) Rating from Weiss RatingsOctober 10 at 6:28 AM | marketbeat.comDid the ReCode Partnership Just Shift Praxis Precision Medicines' (PRAX) Innovation Narrative in Neuroscience?October 8, 2025 | finance.yahoo.comAssessing Praxis Precision Medicines (PRAX) Valuation After Recent Share Price MomentumOctober 8, 2025 | finance.yahoo.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 6, 2025 | marketbeat.comPraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2025 | globenewswire.comReCode Therapeutics Announces Over $29 Million in Additional Financing to Advance Genetic Medicines Pipeline and Provides Corporate UpdateSeptember 30, 2025 | finance.yahoo.comA CT man has to pay $300K+ in fines for insider trading. He got prison too.September 24, 2025 | courant.comCCT man gets 2 months in prison for insider trading scheme that netted $220KSeptember 23, 2025 | msn.comWeston man gets 2 months in prison for insider trading scheme that netted $220KSeptember 23, 2025 | stamfordadvocate.comSAssenagon Asset Management S.A. Raises Position in Praxis Precision Medicines, Inc. $PRAXSeptember 22, 2025 | marketbeat.comJones Trading Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy RecommendationSeptember 19, 2025 | msn.comJones Trading Initiates Coverage on Praxis Precision Medicines (NASDAQ:PRAX)September 19, 2025 | marketbeat.comPraxis Precision Medicines (NASDAQ:PRAX) Shares Up 5% - What's Next?September 18, 2025 | marketbeat.comGoldman Sachs Group Inc. Has $6.71 Million Stock Holdings in Praxis Precision Medicines, Inc. $PRAXSeptember 16, 2025 | marketbeat.comPRAXIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Praxis Precision Medicines, Inc. on Behalf of Praxis Stockholders and Encourages Investors to Contact the FirmSeptember 15, 2025 | globenewswire.comWoodline Partners LP Has $6.66 Million Stake in Praxis Precision Medicines, Inc. $PRAXSeptember 15, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAXSeptember 13, 2025 | prnewswire.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Average Rating of "Moderate Buy" by AnalystsSeptember 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc. - PRAXSeptember 8, 2025 | prnewswire.comPraxis Precision Medicines (PRAX) Has a New Rating from LifeSci CapitalSeptember 6, 2025 | theglobeandmail.comPraxis Precision Medicines to Participate in September Investor ConferencesSeptember 4, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025The Fed Cut Rates: What Now for the S&P 500 and Equity Markets?By Thomas Hughes | September 18, 2025Why Datavault May Be the Penny AI Stock Investors Have Waited ForBy Nathan Reiff | September 22, 2025Costco Investors Will Get a “Special” Treat for ChristmasBy Thomas Hughes | September 29, 2025Treat Your Portfolio With These 3 Spooky Season StocksBy Nathan Reiff | October 8, 2025ALLO, ELVN, PRAX, and IMTX Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.23 -0.28 (-18.54%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.23 0.00 (0.00%) As of 10/10/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Enliven Therapeutics NASDAQ:ELVN$20.82 -0.47 (-2.21%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$20.76 -0.05 (-0.26%) As of 10/10/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Immatics NASDAQ:IMTX$10.36 -0.54 (-4.95%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$10.24 -0.12 (-1.11%) As of 10/10/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Praxis Precision Medicines NASDAQ:PRAX$53.26 -1.50 (-2.74%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$53.28 +0.02 (+0.03%) As of 10/10/2025 07:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook AST SpaceMobile's Big Win: Shares Soar on New Deal With Verizon Microsoft 365 Premium Marks the Next Phase of AI Monetization 3 Reasons to Buy Sprouts Farmers Market Ahead of Earnings Bassett Furniture: Buy Now, Sit Back, and Collect Dividends Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
